Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
West Virginia University
M.D. Anderson Cancer Center
Bayer
Boehringer Ingelheim
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Compass Therapeutics
Pliant Therapeutics, Inc.
Nested Therapeutics, Inc
Kyowa Kirin Co., Ltd.
Compass Therapeutics
Novartis
SkinJect, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Genentech, Inc.
Boehringer Ingelheim
Shanghai Henlius Biotech
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
The Methodist Hospital Research Institute
University of Alabama at Birmingham
OncoC4, Inc.
Pfizer
M.D. Anderson Cancer Center
USWM, LLC (dba US WorldMeds)
KaliVir Immunotherapeutics
Pfizer
Iovance Biotherapeutics, Inc.
Modulation Therapeutics, Inc.
Biocon Limited
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Bio-Thera Solutions
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Bayer
Institut Claudius Regaud